Overview Dividends

(VCEL) Vericel Ord - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92346J1088

Cartilage, Skin, Burn, Autologous, Therapy

EPS (Earnings per Share)

EPS (Earnings per Share) of VCEL over the last years for every Quarter: "2020-09": 0.08, "2020-12": 0.25, "2021-03": -0.07, "2021-06": -0.08, "2021-09": -0.11, "2021-12": 0.09, "2022-03": -0.15, "2022-06": -0.19, "2022-09": -0.14, "2022-12": 0.12, "2023-03": -0.16, "2023-06": -0.11, "2023-09": -0.08, "2023-12": 0.26, "2024-03": -0.08, "2024-06": -0.1, "2024-09": -0.02, "2024-12": 0.38, "2025-03": -0.23, "2025-06": -0.01, "2025-09": 0.1,
EPS Growth (3y CAGR): -6.41%
EPS Trend (3y Corr): 12.2%
Last SUE: 2.17σ
Qual. Beats: 1

Revenue

Revenue of VCEL over the last years for every Quarter: 2020-09: 32.258, 2020-12: 45.229, 2021-03: 34.568, 2021-06: 39.519, 2021-09: 34.506, 2021-12: 47.591, 2022-03: 36.074, 2022-06: 37.046, 2022-09: 38.551, 2022-12: 52.694, 2023-03: 41.017, 2023-06: 45.922, 2023-09: 45.581, 2023-12: 64.996, 2024-03: 51.281, 2024-06: 52.662, 2024-09: 57.905, 2024-12: 75.376, 2025-03: 52.598, 2025-06: 63.24, 2025-09: 67.503,
Revenue Growth (3y CAGR): 9.42%
Revenue Trend (3y Corr): 68.5%
Last SUE: 1.92σ
Qual. Beats: 1
Risk via 10d forecast
Volatility 44.4%
Value at Risk 5%th 69.5%
Relative Tail Risk -4.78%
Reward TTM
Sharpe Ratio -0.66
Alpha -41.71
Character TTM
Hurst Exponent 0.288
Beta 1.121
Beta Downside 0.619
Drawdowns 3y
Max DD 51.72%
Mean DD 14.98%
Median DD 10.17%

Description: VCEL Vericel Ord November 12, 2025

Vericel Corp (NASDAQ: VCEL) is a commercial-stage biopharma focused on autologous cellular therapies for sports-medicine cartilage repair (MACI) and severe-burn treatment (Epicel and NexoBrid) in the U.S. market. The company evolved from Aastrom Biosciences in 2014 and operates out of Cambridge, Massachusetts.

Key operating metrics: FY 2023 net revenue was approximately $71 million, with MACI accounting for roughly 55 % of sales; the burn-care segment grew 12 % YoY driven by increased adoption of NexoBrid. The U.S. sports-medicine market is projected to expand at a 6-7 % CAGR through 2028, while burn-care reimbursements have tightened under Medicare’s prospective payment system, creating pricing pressure.

For a deeper dive into Vericel’s valuation assumptions and scenario analysis, you may find ValueRay’s research platform a useful next step.

VCEL Stock Overview

Market Cap in USD 2,016m
Sub-Industry Biotechnology
IPO / Inception 1997-02-04
Return 12m vs S&P 500 -40.9%
Analyst Rating 4.88 of 5

VCEL Dividends

Currently no dividends paid

VCEL Growth Ratios

Metric Value
CAGR 3y 21.02%
CAGR/Max DD Calmar Ratio 0.41
CAGR/Mean DD Pain Ratio 1.40
Current Volume 402.9k
Average Volume 499.1k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (13.1m TTM) > 0 and > 6% of Revenue (6% = 15.5m TTM)
FCFTA 0.09 (>2.0%) and ΔFCFTA -0.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 68.18% (prev 65.76%; Δ 2.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.13 (>3.0%) and CFO 59.1m > Net Income 13.1m (YES >=105%, WARN >=100%)
Net Debt (-2.40m) to EBITDA (23.8m) ratio: -0.10 <= 3.0 (WARN <= 3.5)
Current Ratio 4.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (51.9m) change vs 12m ago 5.75% (target <= -2.0% for YES)
Gross Margin 73.81% (prev 71.47%; Δ 2.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 61.33% (prev 58.10%; Δ 3.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 22.27 (EBITDA TTM 23.8m / Interest Expense TTM 622.0k) >= 6 (WARN >= 3)

Altman Z'' 2.47

(A) 0.39 = (Total Current Assets 222.0m - Total Current Liabilities 45.6m) / Total Assets 453.3m
(B) -0.88 = Retained Earnings (Balance) -399.5m / Total Assets 453.3m
(C) 0.03 = EBIT TTM 13.9m / Avg Total Assets 421.8m
(D) 2.45 = Book Value of Equity 321.9m / Total Liabilities 131.4m
Total Rating: 2.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 60.27

1. Piotroski 5.50pt
2. FCF Yield 2.16%
3. FCF Margin 16.51%
4. Debt/Equity 0.30
5. Debt/Ebitda -0.10
6. ROIC - WACC (= -5.19)%
7. RoE 4.30%
8. Rev. Trend 68.46%
9. EPS Trend 12.20%

What is the price of VCEL shares?

As of November 21, 2025, the stock is trading at USD 37.85 with a total of 402,902 shares traded.
Over the past week, the price has changed by -4.99%, over one month by +5.08%, over three months by +7.04% and over the past year by -33.90%.

Is VCEL a buy, sell or hold?

Vericel Ord has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy VCEL.
  • Strong Buy: 7
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the VCEL price?

Issuer Target Up/Down from current
Wallstreet Target Price 54.4 43.8%
Analysts Target Price 54.4 43.8%
ValueRay Target Price 36.1 -4.6%

VCEL Fundamental Data Overview November 16, 2025

Market Cap USD = 2.02b (2.02b USD * 1.0 USD.USD)
P/E Trailing = 153.3077
P/E Forward = 53.7634
P/S = 7.7918
P/B = 6.2601
Beta = 1.218
Revenue TTM = 258.7m USD
EBIT TTM = 13.9m USD
EBITDA TTM = 23.8m USD
Long Term Debt = 98.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 27.7m USD (from shortTermDebt, last quarter)
Debt = 98.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.40m USD (from netDebt column, last quarter)
Enterprise Value = 1.98b USD (2.02b + Debt 98.0m - CCE 135.4m)
Interest Coverage Ratio = 22.27 (Ebit TTM 13.9m / Interest Expense TTM 622.0k)
FCF Yield = 2.16% (FCF TTM 42.7m / Enterprise Value 1.98b)
FCF Margin = 16.51% (FCF TTM 42.7m / Revenue TTM 258.7m)
Net Margin = 5.06% (Net Income TTM 13.1m / Revenue TTM 258.7m)
Gross Margin = 73.81% ((Revenue TTM 258.7m - Cost of Revenue TTM 67.7m) / Revenue TTM)
Gross Margin QoQ = 73.46% (prev 73.71%)
Tobins Q-Ratio = 4.36 (Enterprise Value 1.98b / Total Assets 453.3m)
Interest Expense / Debt = 0.16% (Interest Expense 158.0k / Debt 98.0m)
Taxrate = 1.41% (148.0k / 10.5m)
NOPAT = 13.7m (EBIT 13.9m * (1 - 1.41%))
Current Ratio = 4.87 (Total Current Assets 222.0m / Total Current Liabilities 45.6m)
Debt / Equity = 0.30 (Debt 98.0m / totalStockholderEquity, last quarter 321.9m)
Debt / EBITDA = -0.10 (Net Debt -2.40m / EBITDA 23.8m)
Debt / FCF = -0.06 (Net Debt -2.40m / FCF TTM 42.7m)
Total Stockholder Equity = 304.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 13.1m / Total Assets 453.3m)
RoE = 4.30% (Net Income TTM 13.1m / Total Stockholder Equity 304.0m)
RoCE = 3.45% (EBIT 13.9m / Capital Employed (Equity 304.0m + L.T.Debt 98.0m))
RoIC = 4.49% (NOPAT 13.7m / Invested Capital 304.0m)
WACC = 9.69% (E(2.02b)/V(2.11b) * Re(10.15%) + D(98.0m)/V(2.11b) * Rd(0.16%) * (1-Tc(0.01)))
Discount Rate = 10.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.18%
[DCF Debug] Terminal Value 67.34% ; FCFE base≈40.9m ; Y1≈34.1m ; Y5≈25.2m
Fair Price DCF = 6.56 (DCF Value 331.8m / Shares Outstanding 50.6m; 5y FCF grow -20.07% → 3.0% )
EPS Correlation: 12.20 | EPS CAGR: -6.41% | SUE: 2.17 | # QB: 1
Revenue Correlation: 68.46 | Revenue CAGR: 9.42% | SUE: 1.92 | # QB: 1

Additional Sources for VCEL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle